Back to search results

Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

Abroad (travel likely)RecruitingPHASE2

Conditions

Extensive-stage Small-cell Lung Cancer · Liver Metastases

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

    Contact: Study coordinator (Amy Oppenheim) · Amy.Oppenheim@cshs.org · 310-423-3713
    Contact: Principal Investigator (Kamya Sankar, MD)
    Sukhmani Padda, MD (Sub-investigator)
    Ronald Natale, MD (Sub-investigator)
    Karen Reckamp, MD (Sub-investigator)

  • V.A. Ann Arbor Healthcare System, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Brittany Pannecouk, BS) · Britanny.Pannecouk@va.gov · 734-845-3966
    Contact: Study coordinator (Melissa Robinson, MPH) · Melissa.Robinson1@va.gov · 734-222-7474
    Contact: Principal Investigator (Nithya Ramnath, MBBS)
    Garth W Strohbehn, MD (Sub-investigator)
    Michael D Green, MD PhD (Sub-investigator)

  • University of Michigan, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Dominique Dippman) · dippmand@med.umich.edu
    Contact: Principal Investigator (Angel Qin, MD)
    Gregory P. Kalemkerian, MD (Sub-investigator)
Study leads

  • Kamya Sankar, MD

    Principal Investigator

    Cedars-Sinai Cancer

View source on ClinicalTrials.gov(opens in a new tab)